Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Berubicin - CNS Pharmaceuticals

Next Previous
X
Search
Drug Profile

Berubicin - CNS Pharmaceuticals

Alternative Names: Berubicin hydrochloride; Reata 744; RTA 744; WP744

Latest Information Update: 09 Apr 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of Texas M. D. Anderson Cancer Center
  • Developer CNS Pharmaceuticals; WPD Pharmaceuticals
  • Class Amines; Anthracyclines; Antineoplastics; Carboxylic acids; Ethers; Pyrans; Small molecules
  • Mechanism of Action Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Glioblastoma
  • Phase I/II Lymphoma
  • Research Breast cancer; Lung cancer
  • No development reported Ovarian cancer; Pancreatic cancer
  • Discontinued Brain metastases; Neoplastic meningitis

Most Recent Events

  • 05 Apr 2024 WPD Pharmaceuticals terminates a phase I/II trial for Glioblastoma (Second-line therapy or greater) in Poland (IV, Infusion) due to progress made by their licensor, CNS Pharmaceuticals, in the potentially pivotal CNS-201 trial (NCT04915404)
  • 30 Dec 2023 WPD Pharmaceuticals withdraws a phase I trial in Glioma (In children, In adolescents, Second-line therapy or greater), prior to enrolment due to business decision (IV) (NCT05082493)
  • 28 Dec 2023 No recent reports of development identified for preclinical development in Lymphoma in USA (IV)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top